Lumen Bioscience, a Seattle, WA-based clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, closed a $16m Series B financing.
The round was co-led by new investor WestRiver Management and returning investor Bioeconomy Capital, with additional participation from existing investors Avista Development, Columbia Pacific, Lumen’s founders, and Seattle-area angels.
The funding, which brings Lumen’s total equity and non-dilutive investment to $68m, will support continued advancement of the company’s three clinical programs for C. difficile, norovirus and traveler’s diarrhea.
Led by Brian Finrow, co-founder and Chief Executive Officer, Lumen discovers, develops and manufactures biologic drugs and vaccine candidates for several prevalent, worldwide diseases—many of which currently lack any effective treatments.
To date, the company has advanced its lead therapeutic for traveler’s diarrhea into clinical development and has generated preclinical data in its programs directed against norovirus and C. difficile infection. Lumen also commissioned its dedicated cGMP manufacturing plant, which is currently manufacturing approximately 3 kg of drug material per week for its clinical and pre-clinical programs, sufficient for all of its planned clinical development programs.